Disc Medicine (IRON) News
NASDAQ: IRONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
75.14-0.97 (-1.27%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRON news summary
We found 26 recent headlines mentioning Disc Medicine (IRON): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, IRON is down 1.27% at $75.14. The most recent story, "Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update", was published by Nasdaq on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Disc Medicine headlines
- Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdateDisc Medicine, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided a corporate update. The company ended the quarter with cash, cash equivalents, and…NasdaqIRON, BRK.B
- Disc Medicine GAAP EPS of -$1.53 beats by $0.20Seeking Alpha
- Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdateWATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…GlobeNewswire
- Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual MeetingWATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…GlobeNewswire
- Disc Medicine to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…GlobeNewswire
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) - Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.NasdaqABBV, ABT, ACHV, ALVO
- Disc Medicine Consensus Price Target Increased by 12.67% to $118.56The average one-year price target for Disc Medicine (NASDAQGM:IRON) has been revised to $118.56 / share. This is an increase of 12.67% from the prior estimate of $105.23 dated September 29, 2026.…Nasdaq
- Disc Medicine, Inc. Closes Public Offering of 6,000,000 Shares of Common StockOn October 20, 2026, Disc Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of…NasdaqIRON, MOG.B
- Majority of Disc Medicine 6M share offering goes to 10 investors: reportSeeking Alpha
- Why is Disc Medicine stock sliding today?Investing.com
- Disc Medicine sets $75 share price for $450M offeringSeeking Alpha
- Disc Medicine Prices $450 Mln Offering Of Shares At $75/shr To Fund Pipeline Development(RTTNews) - Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 6 million shares of common stock at a public…NasdaqIRON, BRK.A
- Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockWATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…GlobeNewswire
- Disc Medicine Launches $350M Stock Offering Following Positive Phase 3 Results(RTTNews) - Disc Medicine, Inc. (IRON) announced a proposed underwritten public offering of $350 million of its common stock and, for certain investors, pre-funded warrants to purchase common stock.NasdaqIRON, BRK.A
- Disc Medicine launches $350M public offering of common stock and pre-funded warrantsSeeking Alpha
- Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…GlobeNewswire
- Disc Medicine's Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned(RTTNews) - Disc Medicine, Inc. (IRON) reported positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in adults and adolescents with erythropoietic protoporphyria (EPP), with…NasdaqIRON, ET
- Why is Disc Medicine stock surging today?Investing.com
- Disc Medicine surge 60% on positive Phase 3 trial for rare sunlight disorderInvesting.com
- Disc Medicine posts late-stage trial win for lead asset developed with RocheSeeking Alpha
- Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…GlobeNewswire
- Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up(RTTNews) - Disc Medicine, Inc. (IRON) is scheduled to release topline results today from the Phase 3 APOLLO trial evaluating Bitopertin in patients with erythropoietic protoporphyria (EPP), a rare…NasdaqIRON, WSO.B
- Disc Medicine rallies 32% as investors await bitopertin trial resultsSeeking Alpha
- Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…GlobeNewswire
- Notable Monday Option Activity: LMND, IRON, CAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lemonade Inc (Symbol: LMND), where a total of 7,376 contracts have traded so far,…NasdaqLMND, IRON, C
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) - Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.NasdaqAXGN, AZN, BJDX, BMRN